Submitted to: Campylobacter Helicobacter and Related Organisms International Workshop
Publication Type: Abstract Only
Publication Acceptance Date: 6/1/2007
Publication Date: 9/2/2007
Citation: Svetoch, E.A., Eruslanov, B.V., Perelygin, V.V., Mitsevich, E.V., Mitsevich, I.P., Luvchuk, V.P., Svetoch, O.E., Seal, B.S., Stern, N.J., Siragusa, G.R. 2007. Production of a bacteriocin by a poultry derived Campylobacter jejuni isolate with antimicrobial activity against Clostridium perfringens and other Gram positive bacteria.. Campylobacter Helicobacter and Related Organisms International Workshop. Interpretive Summary:
Technical Abstract: We have purified a bacteriocin peptide (termed CUV-3), produced by a poultry cecal isolate of Campylobacter jejuni (strain CUV-3) with inhibitory activity against Gram positive bacteria including Clostridium perfringens (38 strains), Staphylococcus aureus, Staphylococcus epidermidis and Listeria monocytogenes. The bacteriocin CUV-3 was purified to single band homogeneity by various chromatographic techniques. From amino acid sequence analysis and mass spectrometry, bacteriocin CUV-3 was found to be 2,368 Da, and 37 amino acids in length that contained dehydroalanine and methyllanthionine residues. CUV-3 was sensitive to proteases, heat resistant (100 deg. C, 15 min) and resistant to lysozyme and lipase activities. Minimum inhibitory concentrations (MIC’s) of purified bacteriocin CUV-3 ranged from <1 to 6.5 'g/ml for the Gram positive species and from 15 to 62 ug/ml for Gram negative species tested. NCBI-BLAST searches found CUV-3 contained sequences that were 66% identical to portions of the amino acid sequences of hemolysins predicted for Sulfitobacter sp., Roseovarius sp. and Jannaschia sp. of the alpha-proteobacteria. A non-bacteriocin producing Campylobacter jejuni test strain was resistant to the purified bacteriocin (MIC > 100 'g/ml). CUV-3 MIC’s ('g/ml) against representative strains of C. perfringens were comparable to those of several tested antibiotics: chloramphenicol (17.6), vancomycin (0.3), erythromycin (4.4), imipenem (0.5), tetracycline (0.3), piperacillin (0.1), clindamycin (2.2), CUV-3 (0.3). The potential role of bacteriocin production by a specie of the genus Campylobacter within its gut niche is discussed. To our knowledge, this is the first such activity reported for this taxon.